Condition: Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy · Severe Proteinuria Due to Idiopathic Membranous Nephropathy · Sponsor: SynAct Pharma Aps
This study is an exploratory, randomized, double-blind, multicenter, placebo-controlled study with repeated doses of AP1189. The study population will consist of patients with idiopathic membranous nephropathy (iMN) and severe proteinuria who are on ACE inhibitor or angiotensin II receptor blocker treatment.
This description comes directly from the study's public registry record.
Irene Sandholdt · +45 2015 7033 · isa@croxxmed.com
Birgitte Telmer, MD · +45 2015 1221 · bte@croxxmed.com
Always discuss trial participation with your own doctor first.
| Aarhus Universitetshospital | Aarhus, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04456816